Non-Insulin Diabetes Therapies Market

Global Non-Insulin Diabetes Therapies Market Size (2024 to 2032)

The global non-insulin diabetes therapies market was worth US$ 17.17 billion in 2023 and is anticipated to reach a valuation of US$ 28.04 billion by 2032 from US$ 18.13 billion in 2024, and it is predicted to register a CAGR of 5.6% during the forecast period 2024-2032.

MARKET DRIVERS

The major factor driving the growth of the market is the increase in the number of people affected by type 2 diabetes. The figure for people with diabetes is expected to rise to 642 million by 2040. The engagement of companies to find medicines with fewer side effects has contributed a lot to the growth of the market. Non-Insulin drugs, when injected into the body, help the liver to produce Insulin. The Insulin market dominated previously, but the type of Non-Insulin drugs will soon be at the same level as Insulin Type drugs. The change in lifestyle and food habits is the cause of diabetes, and thus, they will push forward market growth.

MARKET RESTRAINTS

The primary challenge for this market is to produce drugs that have fewer side effects and are more effective than the currently used drugs. The benefits of these drugs are still unknown to many, so less awareness is also a challenge. The availability of these drugs to all people classes is also a big challenge as diabetes is a common disease. The general awareness about the functioning and uses of drugs is not known to many, making people more aware is another challenge for this market. The market leaders in this segment are based in a few regions only, and thus the market penetration of the drugs is not so much, which results in low sales and less awareness. The government initiatives about increasing people’s attention are not in huge numbers and thus restrict the growth of the market.

Impact Of COVID-19 on The Global Non-insulin Diabetes Therapies Market

The COVID-19 pandemic is a serious situation right now, and the increasing number of new positive cases is a cause for concern for the whole world. The coronavirus and its effects on the body are being studied by scientists and pharmaceutical companies worldwide. The coronavirus is found to severely affect people who have heart problems or are suffering from diabetes. Thus, the non-insulin drug market is expected to grow during the pandemic as people need to treat heir diabetes so that the coronavirus does not become a deadly catalyst severely affecting the body. The lockdown prevented the supply and demand from being at the same level, and thus, this gap between supply and demand still needed to be filled. The lockdown also affected the movement of people, and the patients who have diabetes were not able to see their doctor, thus hampering the growth of the market.

REPORT COVERAGE

SEGMENTAL ANALYSIS

Non-Insulin Diabetes Therapies Market Analysis By Drug Type

The SGLT-2 inhibitors segment is expected to witness robust growth during the forecast period based on the drug type. The main reason contributing to growth is the minimum side effects of these drugs. These drug types are also very efficient as monotherapy or combination therapy. More detailed research is being carried out to find a new and efficient type of molecule. During the forecast period, Novartis and Ionis Pharmaceuticals products are the significant pipelines SGLT 2 inhibitors are in the process of a clinical study and are expected to launch during the forecast period.Biguanides drug type is currently in a shallow position in terms of market share but is expected to grow at a reasonable rate during the forecast period. These drugs work by reducing the production of glucose that occurs during digestion. Metformin is the only biguanide currently available in most countries for diabetes treatment. Thus set up of new companies and an effective supply chain will ensure the growth of this sub-segment.

REGIONAL ANALYSIS

Geographically, North America had the largest market share in 2023 and is expected to grow at a healthy rate during the forecast period. The increasing prevalence of diabetes is the primary factor supporting the growth rate. The other reasons propelling the market are many ongoing clinical trials and the availability of improved treatment options and healthcare infrastructure. The presence of global players is going to affect the market positively.

Europe had the second-largest market share in 2023 and is expected to grow at a healthy future rate. The increasing number of diabetes cases due to the prevalence of unhealthy lifestyles and the rising quality of healthcare facilities will support the positive growth of this region.

The Asia Pacific market is expected to grow at the fastest rate among other regions. China has more diabetic patients than any other country globally, surpassing India in the recent past. In India, about 62 million people are facing problems related to Diabetics. About 80 thousand deaths are expected to occur in America because of diabetes, and recent studies show us that around 1.4 million people have been diagnosed and treated for Type-2 Diabetes. The market is expected to increase exponentially in the coming years due to the rise in the number of people facing diabetic problems.

KEY PLAYERS IN THE NON-INSULIN DIABETES THERAPIES MARKET

Some of the key competitors participating in the Global Non-Insulin Diabetes Therapies Market profiled in this report are Tobira, Eli Lilly, and Sumitomo Dainippon Pharma, Novo Nordisk, Takeda, Sanofi, Mannkind, Bristol-Myers Squibb, AstraZeneca, Boehringer Ingelheim, and Bayer.

DETAILED SEGMENTATION OF THE GLOBAL NON-INSULIN DIABETES THERAPIES MARKET INCLUDED IN THIS REPORT

This research report on the Global Non-Insulin Diabetes Therapies Market has been segmented and sub-segmented into the following categories.

By Drug Type

• Sulphonylureas     
• Amylin Agonists    
• GLP-1 Agonists & Analogs
• Biguanides             
• Glinides & Meglinitides      
• Sodium-Glucose cotransporter 2 (SGLT2) Inhibitors
• Thiazolidinediones (or Glitazones or TZDs 
• Alpha-Glucosidase Inhibitors         
• Dipeptidyl Peptidase-4 (DPP4) Inhibitors

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• The Middle East and Africa